Table 1.

Summary of genome-wide linkage studies included in the GSMA (ordered by year of publication)

First author	Year	Population	No. families	No. affecteds	GSMA weight	Linkage statistica	Diagnostic criteria	Diseaseb
Garner	2006	US	160	562	1.95	NPL	biopsy; antibodies; DH (3%)c	symptomatic; asymptomatic
Rioux	2004	Finnish	54	168d	1.04	NPL	biopsy; antibodies; DH (13%)c	symptomatic; asymptomatic
Van Belzen	2003	Dutch	67	142d	0.84	MLS	biopsy	symptomatic; asymptomatic
Popat	2002	UK, Sweden, other	24	79d	0.72	NPL	ESPGAN criteria (biopsy)	symptomatic
Liue	2002	Finnish	60	159	0.97	NPL	biopsy; DH (22%)c	symptomatic; asymptomatic
Naluaie	2001	Scandinavian	70	156d	0.90	NPL	ESPGAN criteria (biopsy)	symptomatic; asymptomatic
Kinge	2000	UK	16	50	0.57	NPL	biopsy; antibodies	symptomatic; asymptomatic
Grecoe	1998	I	103	213d	1.02	MLS	biopsy; antibodies	symptomatic; asymptomatic

^aMLS = Maximum likelihood statistic; NPL = non parametric linkage score

^bStudies included patients with symptomatic CD, or asymptomatic CD, diagnosed through screening but without the presence of well-defined CD symptoms

^cDH = dermatitis herpetiformis; percentage of DH cases among affecteds are indicated

^dNumber of affecteds derived from information on number of affected sib pairs/trios etc or from the family trees of affected families

^eStudy included in the previous meta/mega analysis by Babron et al. [7].